SAB Biotherapeutics SABS
NASDAQ SABS
$3.11 +0.04 (+1.30%)
At close: Nov 11, 2026 · 4:00 PM EST

SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026)

Updated

SAB Biotherapeutics (SABS) reported Long-Term Investments of $105.35 million for Q2 2026, down 4.4% from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026) Analysis & Trends

At the end of FY2025, SAB Biotherapeutics posted Long-Term Investments of $46.89 million.

  • Five-year quarterly Long-Term Investments spans a low of $1.24 million in Q1 2024 and a high of $116.16 million in Q3 2021.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $110.24 million (Q1 2026), $46.89 million (Q4 2025) and $50.61 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 4.01 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 387.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 1.60 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - 63.00 Mn
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 268.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 1.45 Bn
10 SAB Biotherapeutics 279.79 Mn -130.87 Mn - 101.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 101.29 Mn
Jun 30, 2026 105.35 Mn
Mar 31, 2026 110.24 Mn
Dec 31, 2025 46.89 Mn
Sep 30, 2025 50.61 Mn
Mar 31, 2024 1.24 Mn
Sep 30, 2021 116.16 Mn
Jun 30, 2021 116.16 Mn
Mar 31, 2021 116.15 Mn
API Access

SAB Biotherapeutics Long-Term Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-investments&ticker=SABS&period=max&api_key=YOUR_API_KEY